fbpx

Why Did Bristol Myers Squibb (BMS) Pay $4.1 Billion for Turning Point Therapeutics?

Turning Point Therapeutics ($TPTX) was recently acquired by BMS for a whopping $4.1 billion in cash. Turning Point’s most advanced molecule is repotrectinib, a potential best-in-class ROS1/TRK/ALK tyrosine kinase inhibitor in Ph. I/II studies for cancer. This article explores the science behind repotrectinib, one of our 2021 Molecules of the Month, what properties make it valuable, and how we know.

request a trial

You don’t have time to read everything, but you can’t afford to fall behind.

Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.

Get ahead now by requesting a trial.



already a member? log in:

Join the Drug Hunter mailing list

to get free content and resources weekly. Trusted by > 5,500 drug hunters worldwide. Unsubscribe anytime.

This field is for validation purposes and should be left unchanged.
Newsletter

Join Subscribers from

…and hundreds more!